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The beneﬁcial effects of probiotics have been described in many
diseases, but the mechanism by which they modulate the immune
system is poorly understood. In this study, we identiﬁed a mixture
of probiotics that up-regulates CD4+Foxp3+ regulatory T cells
(Tregs). Administration of the probiotics mixture induced both T-
cell and B-cell hyporesponsiveness and down-regulated T helper
(Th) 1, Th2, and Th17 cytokines without apoptosis induction. It also
induced generation of CD4+Foxp3+ Tregs from the CD4+CD25− pop-
ulation and increased the suppressor activity of naturally occurring
CD4+CD25+ Tregs. Conversion of T cells into Foxp3+ Tregs is directly
mediated by regulatory dendritic cells (rDCs) that express high lev-
els of IL-10, TGF-β, COX-2, and indoleamine 2,3-dioxygenase. Ad-
ministration of probiotics had therapeutical effects in experimental
inﬂammatory bowel disease, atopic dermatitis, and rheumatoid
arthritis. The therapeutical effect of the probiotics is associated
with enrichment of CD4+Foxp3+ Tregs in the inﬂamed regions. Col-
lectively, the administration of probiotics that enhance the gener-
ation of rDCs and Tregs represents an applicable treatment of
inﬂammatory immune disorders.
regulatory T cell | inﬂammation | atopic dermatitis | inﬂammatory bowel
disease | rheumatoid arthritis
Gastrointestinal microorganisms affect host physiologythrough diverse mechanisms, including modulation of the
host immune system. Probiotics are nonpathogenic micro-
organisms that confer a number of beneﬁcial effects on the
health of the host (1). Among them, species of lactobacilli and
Biﬁdobacteria are prominent probiotics with antiinﬂammatory
properties (2). For example, administration of Lactobacillus casei
suppresses proinﬂammatory responses by increasing IL-10 levels
(3, 4), whereas Lactobacillus acidophilus increases T helper 1
(Th1) type cytokines (5). However, many questions remain
unanswered, such as which probiotic strains are the most effec-
tive in modulation of speciﬁc immune disorders and how orally
administrated probiotics affect the systemic immune system (6).
In this study, we sought to identify which probiotics ormixture of
probiotics could confer potent antiinﬂammatory effects by
increasing CD4+Foxp3+ regulatory T cells (Tregs). The forkhead
family protein Foxp3 is a transcription factor highly expressed in
CD4+ Tregs. It is a regulator of T-cell tolerance and is necessary
for the development and function of Tregs (7). Following in vitro
and in vivo functional studies on Treg generation, we developed a
probiotics mixture that exhibits potent antiinﬂammatory proper-
ties and investigated its modulation of diverse immune disorders.
The probiotics mixture, designated IRT5, consists of a combi-
nation of ﬁve probiotic strains. Oral administration of IRT5
induced T- and B-cell hyporesponsiveness without inducing
apoptosis. IRT5 administration increased the level of
CD4+Foxp3+ Tregs in mesenteric lymph node (MLN) by aug-
menting Foxp3+ levels in CD4+CD25− T cells. Conversion of T
cells into Foxp3+ Tregs is directly mediated by regulatory den-
dritic cells (rDCs) that express increased levels of IL-10, TGF-β,
COX-2, and indoleamine 2,3-dioxygenase (iDO). Administration
of IRT5 suppressed the progression of experimental inﬂamma-
tory bowel disease (IBD), atopic dermatitis (AD) and rheumatoid
arthritis (RA). In addition, migration of Tregs to inﬂammatory
regions in response to chemokines (CCL1 and CCL22) and their
receptors (CCR4 and CCR8) mediated disease suppression.
Results
Probiotics Increase CD4+Foxp3+ Tregs in a CD4+CD25− T-Cell Population.
Probiotic bacteria have potent immunomodulatory effects, but their
mechanism of action is poorly understood. To identify probiotic
strains that could speciﬁcally up-regulate CD4+Foxp3+ Tregs, we
developed an ex vivo screening systemby coculturing freshly isolated
MLN with probiotics. Candidate probiotics, or a mixture of them,
were selectedbasedon thecriteria that showedhigh levels (>4)of the
IL-10/IL-12 production ratio and enhanced Foxp3 expression (>1.5-
fold). These includeL. acidophilus (LA),L. casei (LC),Lactobacillus
reuteri (LR), Biﬁdobacterium biﬁdium (BB), and Streptococcus ther-
mophilus (ST). After determination of the optimal dosage (5 × 108
cfu/day; SI Materials and Methods), candidate probiotic strains,
individually or in combination, were fed to normal healthy BALB/c
mice for 20 days and the population ofCD4+Foxp3+T cells inMLN
was measured by ﬂuorescence-activated cell sorting (FACS). A
mixture of the ﬁve strains (LA/LC/LR/BB/ST) signiﬁcantly (P <
0.005) increased the CD4+Foxp3+ Treg population compared with
control, individual strain, or other mixture groups (Fig. S1 A–C).
Thereafter, all experiments were performed with the mixture of
ﬁve probiotics, designated IRT5. Administration of IRT5 sig-
niﬁcantly (P < 0.005) increased Foxp3 mRNA expression (Fig. 1A)
and protein level (Fig. 1B) compared with the PBS-treated group.
Next, we tested whether increased Foxp3 levels originated from
naturally occurring CD4+CD25+ Tregs (nTregs) (8) or from
induced Tregs in the CD4+CD25− population. Administration of
IRT5 [probiotics (Pro)] signiﬁcantly increased Foxp3 levels (6.5%)
compared with the control PBS-fed group (Cont; 2.8%) within the
population of CD4+CD25− Tregs (Fig. 1C, Upper). In addition,
although IRT5 did not increase the CD4+CD25+ population (Fig.
S1D) and no difference in the CD4+CD25+Foxp3+ population was
observed between the treatment groups (Fig. 1C, Lower), the
CD4+CD25+Tregsof theProgroup showed increasedexpressionof
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Treg-associated molecules [TGF-β and cytotoxic T-lymphocyte-
associated (CTLA)-4; Fig. 1D], resulting in signiﬁcantly (P < 0.05)
elevated suppressor activity compared with Tregs from the Cont
group (Fig. 1E). We also compared the functional difference of
CD4+CD25− effector T cells between PBS- and IRT5-fed groups.
Compared with the Cont group, CD4+CD25− T cells from the Pro
group were hypoproliferative (Fig. S2A) with slightly increased
suppression sensitivity by the CD4+CD25+ Tregs (Fig. S2B). These
observations indicate that administration of IRT5 induced gen-
eration of CD4+Foxp3+ Tregs from the pool of CD4+CD25− cells
and potentiated the suppressor function of CD4+CD25+ nTregs.
Probiotics Induce Hyporesponsiveness in CD4+ T Cells. Next, we tes-
ted whether increased CD4+Foxp3+ Tregs by IRT5 affects the
effector function of T cells and B cells. IRT5 (Pro) or PBS (Cont)
was fed to normal BALB/c mice for 20 days, and CD4+ T cells or
B220+ B cells isolated from spleen (SP) and MLN were stimu-
lated with phorbol 12-myristate 13-acetone (PMA)/ionomycin.
The relative transcript levels of Th1 (IL-2, IFN-γ, and TNF-α),
Th2 (IL-4 and IL-10), and Th17 (IL-17) cytokines were measured
by real-time PCR. Administration of IRT5 signiﬁcantly (P< 0.05–
0.005) reduced the levels of all tested cytokines in both CD4+ T
cells (Fig. 2A) and B cells (Fig. S3A). In addition, administration
of IRT5 induced hyporesponsiveness in both CD4+ T cells (Fig.
2B) and B cells (Fig. S3B) without inducing apoptosis (Annexin
V+/7-aminoactinomycin D (7-ADD)+) (Fig. S3 C and D).
Probiotics Administration Induces CD11c+ rDCs, Which, in Turn, Promote
Generation of CD4+Foxp3+ T Cells. We next investigated the role of
CD11c+ dendritic cells (DCs) in the generation of CD4+Foxp3+
Tregs by IRT5. MLN CD11c+ DCs isolated from each treatment
group were stimulated with PMA/ionomycin, and the levels of tol-
erogenic DC markers were measured. Administration of IRT5
signiﬁcantly up-regulated the expression levels of IL-10, TGF-β,
iDO, and COX-2 (Fig. 3A) without increasing CD103+DCs, which
are recognized as a marker of mucosal DCs generating Foxp3+
Tregs (9) (Fig. S4A).We further tested whether rDCs generated by
IRT5 have the potential to induce Foxp3+ Tregs. MLN DCs from
each group were cocultured with DO11.10 CD4+T cells labeled
with carboxyﬂuorescein diacetate succinimidyl ester (CFSE) in the
presence of Ova peptide (0.3 μg/mL), with or without exogenous
TGF-β, which induces the generation of inducedTregs in vitro. The
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Fig. 1. Probiotics increase CD4+Foxp3+ Tregs. Foxp3 levels were analyzed by real-time PCR (A) or FACS (B) in SP and MLN CD4+ T cells from mice fed either PBS
(Cont) or IRT5 (Pro) for 20 days. (C) Levels of Foxp3+ cells were analyzed in CD4+CD25+ and CD4+CD25− populations. (D) Expression levels of Treg-associated
molecules were compared in MLN CD4+CD25+ Tregs from each group. GrznB, Granzyme B. (E) Suppressor activity of CD4+CD25+ Tregs was measured by T-cell
proliferation assay. Tregs from each treatment group (Cont or Pro) were cocultured with responder cells (CD4+CD25−) at various ratios of Treg/responder cells.
The proliferation level of responder cells alone was assigned a value of 100%. Data are the average of three independent experiments (10 mice per group);
error bars indicate SD. *P < 0.05; **P < 0.005; ***P < 0.001.
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Fig. 2. Probiotics induce hyporesponsiveness in CD4 T cells. (A) Levels of cytokine expression in CD4+ T cells were analyzed by real-time PCR. Cytokine
expression in spleen CD4+ T cells of Cont group mice was set at 100%. (B) Proliferation of CD4+ T cells from the Cont or Pro group mice was measured after
stimulation with anti-CD3/anti-CD28. Data are from 10mice per group; error bars indicate SD. Data are representative of three independent experiments. **P<
0.005; ***P < 0.001.
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CD4+Foxp3+ Treg population was then analyzed by FACS. MLN
DCs from Pro mice preferentially converted T cells into
CD4+Foxp3+ T cells compared with the Cont group in both the
absence (18.3% Pro vs. 10.8% Cont) and presence (25% Pro
vs.10.5% Cont) of TGF-β (Fig. 3B). In addition, CD4+ T cells
cocultured with IRT5-treated MLN DCs showed signiﬁcantly
reduced proliferation compared with control (30% Pro vs. 61%
Cont) (Fig. S4B) because of their increased Treg population (Fig.
3B). Like in vivo-generatedTregs by IRT5 administration (Fig. 1C),
up-regulation of Foxp3 levels were mainly observed in the
CD4+CD25− population (13.3% Pro vs. 6.4% Cont) (Fig. 3C). To
characterize the functional property of rDCs generated by IRT5
further, we tested whether addition of inhibitors for rDCs could
inhibit rDC-dependent Foxp3+Treg generation.CD4+Tcellswere
coculturedwithMLNCD11c+DCs in the presence of various types
of inhibitors, andFoxp3+populations thenwere analyzed byFACS.
Addition of inhibitors such as anti-TGF-β, celecoxib (a COX-2
inhibitor), or 1-methyl-d-tryptophan (1-MT, an iDO inhibitor) sig-
niﬁcantly down-regulatedFoxp3+ generation (Fig. 3D andFig. S4C
and D). Collectively, these results suggest that IRT5 facilitates the
generation of rDCs that have the capacity to convert Foxp3−T cells
into Foxp3+ Tregs.
Probiotics Suppress Experimental Immune Disorders. Next, we tested
whether IRT5 could ameliorate immune disorders such as IBD,
AD, and RA. Trinitrobenzesulfonic acid (TNBS) colitis is a well-
characterized animal model of Th1-mediated IBD, and it mimics
human Crohn’s disease. Mice were fed with PBS or IRT5 daily for
20 days, and the intestinal colitis was established by an intrarectal
injection of TNBS. The prevention effects of IRT5 were moni-
tored by measuring survivalship, weight loss, colitis grade, gross
morphology, and histology of the colon (Fig. 4 and Fig. S5).
Retardation of IBD progression in the Pro group was associated
with reduction of all tested criteria for disease evaluation,
including inﬂammatory cytokines such as IL-17, IFN-γ, andTNF-α
(Fig. 4C).
Next, we tested whether IRT5 also has a therapeutical effect on
AD, which is known to be a typical Th2-mediated immune dis-
order. A murine AD model was established by alternate painting
of house dust mite extract and dinitrochlorobenzene. Two weeks
after AD induction, IRT5 or PBS was administered to mice with
AD and the parameters for AD progression were measured.
Treatment with IRT5 signiﬁcantly (P < 0.05) inhibited the clinical
symptoms of AD progression (Fig. 5A and Fig. S6A) by reducing
IgE levels [total IgE level (Fig. 5C) and mite-speciﬁc IgE level
Fig. 3. Probiotics induce CD11c+ rDCs. (A) CD11c+ DCs isolated from MLN of Cont or Pro group mice were stimulated with PMA/ionomycin. The levels of
immunoregulatory molecules were measured by real-time PCR. (B) CD11c+ DCs from each group were cocultured with Do11.10 CD4+ T cells labeled with CFSE
and ovalbumin peptide (0.3 μg/mL) in the absence (−) or presence (+) of exogenous TGF-β. (C) Levels of Foxp3+CD25− and Foxp3+CD25+ populations were
measured by FACS. (D) MLN CD11c+ DCs from IRT5-fedmice were cocultured with CD4+ T cells in the presence of ovalbumin peptide and inhibitors for rDCs. w/o,
without. After coculture, alteration of the Foxp3+ population was measured by FACS. Data are from 10 mice per group and are the average of three inde-
pendent experiments.
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Fig. 4. Probiotics suppress experimental colitis. (A) Changes in gross intestines were evaluated 3 days after induction of colitis. (B) Histological analysis after
H&E staining to detect lymphocyte inﬁltration. (C) Real-time PCR was performed to analyze changes in the expression of proinﬂammatory cytokines in
response to probiotics administration. Data are from 20 mice per group; error bars indicate SD. Data are representative of three independent experiments.
**P < 0.005; ***P < 0.001.
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(Fig. S6C)], inﬁltrated lymphocytes and granulocytes (Fig. 5B and
Fig. S6B), and levels of AD-associated cytokines, such as IL-4, IL-
5, IL-10 and IL-13 (Fig. S6 E and F). In addition, administration
of IRT5 signiﬁcantly slowed the progression of collagen-induced
experimental RA by reducing clinical symptoms, lymphocyte
inﬁltration into the joint, and levels of inﬂammatory cytokines,
while increasing Foxp3 levels (Fig. S7).
EnrichedCD4+Foxp3+ TregCells at Sitesof InﬂammationAreAssociated
with Disease Suppression.CD4+Foxp3+ Tregs suppress pathogenic
effector cells through cell-to-cell contact or focal increment at the
inﬂamed sites (10–12). Thereby, we measured the population of
CD4+Foxp3+ Tregs at the sites of disease progression. Mice with
AD or IBD were treated with IRT5 or PBS, and the population of
CD4+Foxp3+ T cells at the inﬂammatory sites (colon in exper-
imental IBD and ear in AD) was determined by FACS and
immunohistochemistry (IHC). The Pro group showed signiﬁcantly
increased CD4+Foxp3+ T cells compared with the Cont group in
both IBD (31% vs. 14.2%; Fig. 6A) and AD (32.9% vs. 4.6%; Fig.
6B) mice. Enrichment of Foxp3+CD4+ Tregs in the IRT5-treated
group was also conﬁrmed by IHC in both the inﬂammatory colon
and atopic ear (Fig. 6C and Fig. S8).
Increased Chemoattractants for Treg Induce Migration of CD4+Foxp3+
Tregs to Inﬂamed Regions. Next, we checked whether increased
CD4+Foxp3+ Tregs are directly related to the therapeutical
effects of IRT5 in multiple types of immune disorders. As in
normal mice (Fig. 1), IRT5 administration in disease conditions
also signiﬁcantly increased the CD4+Foxp3+ Treg populations in
MLN (Fig. S9A andB).We further tested whether enriched levels
of CD4+Foxp3+ Tregs in the colon (IBD) or ear (AD) (Fig. 6C)
are associated with increased chemoattractants for CD4+Foxp3+
Tregs, resulting in their migration fromMLN to the inﬂammatory
sites. We measured the expression levels of chemokines and their
receptors involved in the recruitment of CD4+Foxp3+ Tregs in
AD mice. Indeed, the group fed with IRT5 (Pro) showed sig-
niﬁcantly increased expression levels of CCL1 and CCL22 in the
ear tissues (Fig. 7A) and their receptors, CCR4 and CCR8 (13–
15), in ear residual CD4+ T cells (Fig. 7B). We further examined
the migratory properties of CD4+Foxp3+ Tregs generated in
MLN by IRT5 administration to the inﬂammatory region by
means of an adoptive transfer experiment. CD4+ T cells isolated
from MLN of the mice fed PBS or IRT5 for 20 days were labeled
with CFSE and then adoptively transferred to AD mice by i.p.
injection (Fig. S9C). The CFSE+Foxp3+ populations in the ear of
AD mice were measured by IHC (Fig. 7C and Fig. S10). As a
negative control, the same numbers of unlabeled CD4+ T cells
were transferred (Fig. 7C, Left, and Fig. S10). Ear sections from
each group of mice were stained by Hoechst (blue) and anti-
Foxp3 antibodies (red). CFSE+(CD4+)Foxp3+ cells were detec-
ted by bright green staining as a result of overlap of the colors. The
Pro group (Fig. 7C, Right, and Fig. S10) showed much higher
numbers of CFSE+(CD4+)Foxp3+ cells compared with the Cont
group (Fig. 7C, Middle, and Fig. S10) in the ear regions of AD
mice. Conclusively, these results suggest that CD4+Foxp3+ Tregs
generated by administration of IRT5 in MLN migrated to the
inﬂamed sites to mediate suppression of disease progression.
Discussion
In this study, we developed a probiotics mixture (designated
IRT5) with potent anti-inﬂammatory properties and examined its
modulation efﬁcacy of experimental immune disorders. Admin-
istration of IRT5 induced rDCs, which, in turn, potentiated gen-
eration of CD4+Foxp3+ Tregs in MLN. Enrichment of
CD4+Foxp3+ Tregs at sites of inﬂammation is associated with up-
regulated levels of chemoattractants (CCL1 and CCL22), which
inhibited the progression of experimental immune disorders.
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Little information is available on the mechanism by which
administration of probiotics generates regulatory T-cell pop-
ulations. In the present study, we present evidence that ingestion
of a speciﬁc probioticsmixture (IRT5) can generate CD4+Foxp3+
Tregs in MLN. The immunomodulatory action of IRT5 was not
achieved by increasing the expression of immunosuppressive
cytokines such as IL-10 or TGF-β but, instead, by suppressing the
expression of inﬂammatory (IL-17, IFN-γ, and TNF-α) and anti-
inﬂammatory (IL-10) cytokines in both T cells (Fig. 2) and B cells
(Fig. S3 A and B) without apoptosis induction (Fig. S3 C and D).
Administration of IRT5 did not increase the number of nTregs
(Fig. 1C) but did increase their suppressor capacity (Fig. 1 D and
E). Interestingly, ingestion of IRT5 up-regulated Foxp3 levels
more than 2-fold in the CD4+CD25− population (Fig. 1C).
How do probiotics promote the generation of CD4+Foxp3+
cells? They may not directly generate adaptive Tregs but induce
rDCs to exhibit immunological tolerance. Indeed, probiotics
(IRT5) alone without rDCs failed to induce Foxp3+ Tregs when
they were cocultured with CD4+ T cells up to 3 days (Fig. S4E).
Recently, two studies reported that oral administration of a cer-
tain probiotic strain could increase Foxp3+ Tregs (16, 17) in the
SP. However, previous studies did not provide any clue as to how
probiotics can enhance the generation of CD4+Foxp3+ Tregs. In
this study, we provided evidence and sequential scenarios for how
IRT5 can generate CD4+Foxp3+ Tregs in MLN. Administration
of IRT5 probiotics induced rDCs, which, in turn, promoted gen-
eration of CD4+Foxp3+ T cells in MLN (Fig. 3). DCs can directly
present antigens from commensal bacteria to MLN and interact
with T and B cells to maintain noninﬂammatory immune
responses (18, 19). Treatment with IRT5 generates CD11c+ DCs
that express markers of rDCs such as IL-10, TGF-β, COX-2, and
iDO (20). COX-2 is one of several active molecules to generate
Foxp3+ Tregs in various types of systems, including cancer (21,
22). iDO DCs promote the development of Treg cells (23).
Therefore, we postulated that IRT5 generated tolerogenic DCs,
which, in turn, induced generation of CD4+Foxp3+ Tregs.
Indeed, we demonstrated that rDCs generated by IRT5 could
convert CD4+CD25− T cells into CD4+CD25−Foxp3+ T cells
(Fig. 3 B and C), in which, however, addition of inhibitors for
TGF-β, COX-2, or iDO strongly inhibited the generation of
Foxp3+ Tregs (Fig. 3D and Fig. S4C). Mucosal CD103+ DCs play
important roles in the generation of Foxp3+ Tregs through in a
retinoic acid TGF-β-dependent manner (24). However, rDCs
generated by IRT5 administration were not CD103+CD11c+ but
CD103c−CD11c+. IRT5 administration did not up-regulate
CD103+ (Fig. S4A), and blockade of retinoic acid (LE540, a
retinoic acid inhibitor) did not alter the levels of rDC-mediated
Foxp3+ Tregs (Fig. S4D). How does the immune system recognize
to the generation of rDCs in MLN? Currently we are trying to
identify and elucidate the role of the pattern recognition receptors
(e.g., Toll-like receptor-2 and other TLRs) (25, 26) and under-
lying signal transduction pathways (e.g., Myd88 dependency).
Administration of IRT5 increased the numbers of adaptive
Tregs (CD4+CD25−Foxp3+) both in healthy mice (Fig. 1) and in
IBD and AD mouse models (Fig. S9 A and B). The protective
effect of IRT5 is associated with highly up-regulated levels of
CD4+Foxp3+ Tregs in the inﬂammatory regions (Fig. 6 and Fig.
S8). Tregs are able to recirculate through lymphoid tissues and to
enter inﬂamed sites (27) by expressing speciﬁc chemokines and
their receptors (28). We also found that administration of IRT5
signiﬁcantly increased the expression of chemokines (CCL1 and
CCL22; Fig. 7A) and their receptors (CCR4 and CCR8; Fig. 7B)
(13–15). Furthermore, the results of an adoptive transfer experi-
ment revealed that Tregs generated in MLN by IRT5 can migrate
to the inﬂammatory sites of AD mice (Fig. 7C and Fig. S10).
Decreased Tregs are associated with inﬂammatory diseases,
including IBD and AD (29, 30). Interestingly, experimental IBD
and AD mice also exhibited reduced numbers of CD4+Foxp3+
Tregs in inﬂamed sites comparedwith controlmice (Fig. 6 andFig.
S8). Hence, enriched CD4+Foxp3+ Tregs induced by IRT5 may
suppress inﬂammatory effector T cells at the sites of inﬂammation,
resulting in a protective effect in these disease models.
One of the challenging issues in the probiotic ﬁeld is how to
identify potent immunoregulatory probiotics among the hundreds
of probiotic strains. Recently, we developed an ex vivo screening
system to identify immune-regulatory probiotics inducing IL-10
and Foxp3+ Tregs but reducing proinﬂammatory cytokines. After
coculturing MLN total cells with each probiotic strain for 3 days,
probiotic strains that showed a high level (>4) of the IL-10/IL-12
ratio and more than a 1.5-fold increase in Foxp3+ levels were
selected.Amixture of selected strains (IRT5) showedmore potent
disease suppression efﬁcacy than single or three- and four-strain
combinations (Fig. S11). Interestingly, heat-inactivated IRT5 did
not have any signiﬁcant therapeutical effects. Why does a combi-
nation of probiotics showmore potent therapeutical effects than a
single probiotic strain (Fig. 1 and Fig. S11)? The combination of
three (Fig. S11; multistrain combination) and four or ﬁve (Fig.
S11; multispecies combinations) strainsmay enhance colonization
and adhesion activity (31, 32) compared with a single strain,
resulting in increased immune-modulatory activities by which
Foxp3+ Tregs were generated. How does IRT5 modulate disease
progression, regardless of the site of inﬂammation, in inﬂamma-
tory diseases? We suggest the following sequence of events. First,
DCs recognize and process the administered IRT5 probiotics.
During this process,CD11c+DCsare converted into rDCs that are
able to convert CD4+Foxp3− T cells into CD4+Foxp3+ Tregs.
Next, the generated Tregs in MLN migrate to the inﬂammatory
sites, directed by chemoattractant produced at the inﬂammatory
sites, resulting in an enrichment of Tregs. Finally, Tregs abolish the
inﬂammatory effector function of pathogenic T cells, which leads
to suppression of disease progression.
A B
6
7
A
Cont
Pro
*** C
3
3.5
A
Cont
Pro**
**
unlabeled ProCont
2
3
4
5
R
el
at
iv
e 
m
R
N
* 1
1.5
2
2.5
R
el
at
iv
e 
m
R
N
Blue:Hoeschst,  Red:Foxp3, Green:CFSE
0
1
CCL1 CCL4 CCL22 0
0.5
CCR4 CCR5 CCR8
Fig. 7. Increased chemoattractant expression leads to enrichment of Tregs in the inﬂamed region. The expression levels of chemokines in MHC class II-
positive antigen-presenting cells (A) and their receptors in CD4+ T cells (B) were analyzed by quantitative real-time PCR. (C) CFSE-labeled T cells obtained from
MLN of Cont and Pro groups were adoptively transferred to AD mice. The migration of CFSE+(CD4+)Foxp3+ Tregs to the ear of AD mice was analyzed by IHC.
The arrows indicate CFSE+(CD4+)Foxp3+ Tregs. Data are from 10 mice per group; error bars indicate SD. Data are representative of three independent
experiments. *P < 0.05; **P < 0.005; ***P < 0.001.
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In summary, the combined probiotics in IRT5 exerted potent
immunomodulatory effects by up-regulating or potentiating the
generation of Tregs by tolerogenic DCs in MLN. In addition,
migration of CD4+Foxp3+ Tregs to sites of inﬂammation effec-
tively suppressed disease progression. Our results present evi-
dence of the generation of CD4+CD25−Foxp3+ Tregs in
response to probiotics, an effect that may be therapeutically useful
for the modulation of inﬂammatory immune disorders.
Materials and Methods
Probiotic Strains. The probiotics mixtures of live bacteria contained 1 × 109
cfus of each of the following strains: BB, LA, ST, LC, and Lactobacillus leuteri.
To test the effect of single strains, each strain was administered to mice at a
concentration of 5 × 108 cfus per 100 μL. Probiotic strains used in this study
were purchased from Cell Biotech Co., Ltd.
DC-Dependent Treg Cell Differentiation Assay. MLN CD11c+ DCs were isolated
from each group and cultured with splenic CD4+ T cells isolated from
Do11.10 transgenic mice or WT BALB/c mice labeled with 10 mM CFSE
(Invitrogen) in the presence of ovalbumin peptide (0.2 μg/mL) and soluble
anti-CD3 (1 μg/mL) with or without mouseTGF-β (2 ng/mL, PeproTech; cata-
log no. 100-21c) for 4 days. To test the roles of rDC-related molecules in rDC-
mediated Treg generation, inhibitors were added such as anti-IL-10 (10 μg/
mL; BD PharMingen), anti-TGF-β (10 μg/mL; R&D Systems), LE540 (0.1 or 1
μM; Wako), celecoxib (50 μM; Biovision) and 1-MT (20 μM; Sigma). The
population of Foxp3+ Treg cells was analyzed by FACS.
Adoptive Transfer Experiment. After 20 days of oral administration of PBS or
probiotics (IRT5), mice were killed and MLN CD4+ T cells were isolated from
each group. A total of 5 × 106 CD4+ T cells were labeled with 5 μM CFSE for
15 min at 37°C and adoptively transferred into AD-induced mice by i.p.
injection. Twenty-four hours after adoptive transfer, mice were killed and
ears were removed to examine the migration of Tregs by IHC (33).
Statistical Analysis. The Student’s t test was used to determine signiﬁcance,
and P < 0.05 was considered signiﬁcant.
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